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HIV-exposed, uninfected (HEU) infants receiving neo-
natal postexposure prophylaxis with zidovudine showed 
nonsignificant trends of lower CD4 and CD8 T cells as well as 
CD19 B cells than those who did not, suggesting toxicity that 
might impact the overall health of HEU children.
Keywords.  adjusted mean difference; HIV-exposed unin-
fected infants; lymphocyte subsets; neonatal postexposure pro-
phylaxis; zidovudine.
Over the last decade, the risk of mother-to-child transmission 
(MTCT) of HIV has declined to virtually zero in resource-rich 
countries due to improved prevention strategies, including 
especially the widespread use of combination antiretroviral 
therapy (cART) during pregnancy, leading to full suppression 
of the maternal HIV plasma viral load (pVL) [1, 2]. In 2016, 
for the first time in a high-income country, applying the well-
accepted principle of undetectable  =  untransmittable [3] to 
MTCT prevention measures, neonatal postexposure prophy-
laxis (PEP) has been abandoned in Switzerland in HIV-exposed 
newborns if maternal HIV plasma viral load (pVL) is fully sup-
pressed in the last trimester of pregnancy [4].
Studies in low- [5, 6] and high-income countries [7] showed 
higher incidence of severe infections in HIV-exposed, unin-
fected (HEU) infants within their first 2 years of life compared 
with unexposed children. Additionally, in low-income coun-
tries, HEU infants experience higher mortality rates compared 
with unexposed children [8, 9]. The underlying mechanisms of 
these observations are not known, but HIV proteins have been 
shown to cross the placental barrier and to influence progenitor 
cells, leading to immunologic abnormalities in HIV-exposed 
infants, even without being HIV-infected [10]. Several studies 
have shown reduced numbers of CD4 T cells and increased 
numbers of both CD8 T and CD19 B cells among HEU infants 
compared with their unexposed peers [10–13]. Additionally, 
detectable hematological toxicity of neonatal PEP with zidovu-
dine (AZT), mainly neutropenia and anemia, has been previ-
ously described [14].
In this study we aim to analyze the impact of AZT-based neo-
natal PEP on lymphocyte subsets and hematological parameters 
in HEU children from birth to 24 months of age.
METHODS
Setting, Patients, and Data Sources
HEU children born between January 2003 and January 2018 
and cared for at the University Children’s Hospital Zurich were 
included in the study if they were participating from birth in 
the Swiss Mother and Child HIV Cohort Study (MoCHiV) and 
the Swiss HIV Cohort Study (SHCS; www.shcs.ch) and written 
informed consent was provided. A child was considered HIV-
uninfected if fourth-generation combination HIV-1/2 immu-
noassay testing was negative between 18 and 24 months of age. 
Postnatal AZT exposure was defined as administration of neo-
natal PEP with AZT for at least 2 weeks.
Lymphocyte subsets and hematological parameters were 
evaluated at 1, 2, 6, and 24 months of age during routine visits 
and included absolute counts and percentage of CD4 and CD8 T 
cells and CD19 B cells, as well as hemoglobin levels, neutrophil 
counts, red blood cell (RBC) counts and their mean corpuscular 
volume (MCV). All measurements were performed in certified 
laboratories at our institution. Cell populations were compared 
with age-dependant normal ranges. Hemoglobin and neutro-
phil counts outside the normal range were graded according to 
the Division of AIDS (DAIDS) table for grading the severity of 
adult and pediatric adverse events [15]. The data for the analysis 
were extracted from the patient records and completed with in-
formation regarding the mothers from the SHCS database.
Statistical Analysis
Categorical variables were compared using the Fisher exact test. 
Continuous variables were analyzed with the Mann-Whitney U 
test. Linear multivariate mixed models, allowing for repeated 
measures, were constructed to determine the effect of AZT-based 
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neonatal PEP on hematological and immunological parameters 
over the period of 2, 6, and 24 months of age adjusting for dif-
ferent maternal (last maternal CD4 counts, RNA viral load and 
CDC classification before delivery, maternal cART type, and 
duration during pregnancy) and neonatal (age, sex, ethnicity, 
and gestational age) characteristics. Parameters with statistically 
significant associations in the linear multivariate mixed models 
were additionally included as covariates in a multivariate logistic 
regression to identify risk factors for hematological toxicity. 
Two-tailed P values <.05 were considered statistically signifi-
cant. Data analysis was performed using IBM SPSS Statistics for 
Windows, version 25.0 (IBM Corporation, Armonk, NY, USA).
Ethics
MoCHiV and SHCS have both been approved by the Ethics 
Committee Zurich (BASEC-Nr. PB_2016-01102).
RESULTS
Among 178 HEU infants included in the analysis, 25 (14%) did 
not receive any neonatal PEP after birth. Eighty-two (53.6%) 
neonatal PEP recipients and 1 (4%) of the infants without PEP 
were born to mothers with AZT-containing cART during preg-
nancy (P <  .001). No deaths occured in the study population. 
The clinical and demographic characteristics of the infants and 
their mothers are shown in Supplementary Table 1.
Lymphocyte Subsets
In the linear multivariate mixed models, lower mean CD4 
T-cell counts were independently associated with older age 
(24  months vs 1, 2, and 6  months) and black ethnicity (at 6 
and 24 months), whereas lower mean CD8 T-cell counts were 
independently associated with older age (24 months vs 1 and 
6  months), black ethnicity (at 24  months), and last maternal 
CD4 T-cell counts <200 cells/mm3 (at 24 months, vs >500 cells/
mm3). Lower mean CD19 B-cell counts were associated with 
older age (24 months vs 2 and 6 months) and maternal cART 
start in the first trimester (at 24  months, vs third trimester) 
(Supplementary Table 2).
Overall, there were no statistically significant differences in 
either absolute CD4 and CD8 T-cell counts or absolute CD19 
B-cell counts comparing adjusted means between HEU infants 
who received neonatal PEP and those who did not (Table 1). 
In the graphical representation, unadjusted mean CD4 and 
CD8 T-cell counts were lower in neonatal PEP recipients up to 
6 months and 2 years of age, respectively, compared with infants 
without PEP. Unadjusted mean absolute CD19 B-cell counts, on 
the other hand, were lower in infants receiving neonatal PEP 
only at the age of 1  month. For comparison, the well-known 
increase of MCV under AZT was only observed up to the age of 
2 months in neonatal PEP recipients (Figure 1).
Based on previous reports on gender differences in lympho-
cyte populations in HEU children [16] and on the association 
of black ethnicity with lower white blood cell (WBC) count 
[17], we performed a subgroup analysis in HEU infants with at 
least 1 parent of sub-Saharan African origin as well as in male 
HEU infants. Children of black ethnicity who received neonatal 
PEP had significantly lower mean CD4 and CD8 T-cell counts 
during the first 24 months after birth compared with their peers 
not receiving neonatal PEP (CD4: adjusted mean difference, 
–495 cells/mm3; 95% confidence interval [CI], –938 to –50 
Table 1. Adjusteda Mean Lymphocyte Subsets and RBC Levels Over Time Period by Postpartum AZT Exposure Status









Nob NeoPepc Mean Nob NeoPepc Mean Nob NeoPepc Mean
Parametersd (n = 25) (n = 153) Difference P Value (n = 25) (n = 153) Difference P Value (n = 25) (n = 153) Difference P Value
CD4 counts, cells/mm3 2737 2534 203 .187 2869 2623 245 .202 2685 2481 190 .194
   (–99 to 505)    (–147 to 597)    (–116 to 496)  
CD8 counts, cells/mm3 860 834 26 .697 914 880 33 .684 958 934 24 .744
   (–104 to 155)    (–127 to 193)    (–120 to 168)  
CD19 counts, cells/mm3 1177 1106 71 .417 1441 1311 129 .259 1369 1224 145 .139
   (–101 to 243)    (–96 to 355)    (–48 to 338)  
RBC counts, T/mm3 3.213 3.062 0.151 .026 3.715 3.582 0.133 .058 4.060 3.899 0.161 .024
   (–0.02 to 0.28)    (–0.005 to 0.27)    (–0.02 to 0.3)  
MCV, fl 91.068 93.947 –2.879 .004 85.327 86.773 –1.145 .142 81.95 83.45 –1.498 .122
   (–4.8 to –0.94)    (–3.38 to 0.49)    (–3.4 to 0.4)  
Abbreviations: AZT, zidovudine; cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention; HEU, HIV-exposed, uninfected; MCV, mean corpuscular volume; 
NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; RBC, red blood cell.
aModels were adjusted for age, sex, ethnicity, gestational age, last maternal CD4 counts and RNA viral load before delivery, maternal cART exposure during pregnancy (AZT, PI, NNRTI), 
trimester of cART start, and last maternal CDC classification. 
bHEU infants who did not receive neonatal postexposure prophylaxis.
cHEU infants who received neonatal postexposure prophylaxis with AZT 2 mg/kg every 6 hours for at least 2 weeks.
dAge-dependant reference ranges in cells/mm3 at 2 months/6 months/24 months: CD4: 2100–4900/1500–5100/1000–4600; CD8: 500–1600/600–2200/500–2300; CD19: 770–1990.
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cells/mm3, P = .029; CD8: adjusted mean difference, –198 cells/
mm3; 95% CI, –386 to –10 cells/mm3, P = .039). For male HEU 
children, no significant difference in lymphocyte subsets was 
found between the 2 groups.
Hematological Toxicity
Clinically relevant anemia, defined as grade 2 toxicity or higher, was 
seen in 23.5% of all HEU children at 1 and in 19.8% at 2 months 
of age. In multivariate logistic regression analysis, the use of pre-
natal AZT-containing cART in the mother was the only significant 
risk factor for anemia (odds ratio [OR], 2.81; 95% CI, 1.2 to 6.6; 
P = .016) within the first month of life (Supplementary Table 3). 
Neonatal PEP was not associated with clinically relevant anemia 
in this analysis, but in the linear multivariate mixed model RBC 
levels were significantly lower at 2 months (adjusted mean differ-
ence, 0.15 T/mm3; 95% CI, –0.02 to 0.28 T/mm3; P =  .026) and 
24 months (adjusted mean difference, 0.16 T/mm3; 95% CI, –0.02 
to 0.3 T/mm3; P = .024) of life in infants receiving neonatal PEP 
compared with those who did not receive neonatal PEP (Table 1).
Clinically relevant neutropenia, defined as grade 2 toxicity or 
higher, was seen in 3.3% of HEU infants at 1 month and 6.8% 
at 2  months of age. No significant difference was found with 
respect to child ethnicity or exposure to maternal AZT or neo-
natal PEP (Supplementary Table 3).
DISCUSSION
In our analysis, no statistically significant differences in mean 
CD4 and CD8 T-cell or CD19 B-cell levels during the first 
24 months of life were observed in HEU infants receiving neo-
natal PEP with AZT compared with those not receiving PEP. But 
even if not statistically significant, a consistent trend of lower ad-
justed means during the first 24 months of life in HEU infants 
receiving neonatal PEP compared with those not receiving PEP 











































































































































Figure 1. Unadjusted means (with 95% CI) for changes in distribution of CD19 B cells (A), CD4 (B) and CD8 (C) T cells as well as MCV (D) with age by neonatal PEP exposure 
status. MCV, mean corpuscular volume; PEP, postexposure prophylaxis.
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models, especially for absolute CD4 T cells. The limited sample 
size and the resulting reduced statistical power may explain the 
lack of statistical significance. Although measured lymphocyte 
levels were consistently within the age-dependent normal ranges, 
which leads us to question the clinical significance of the observed 
differences, these findings suggest a negative influence of AZT-
based neonatal PEP on T and B lymphocyte counts. Additionally, 
the use of prenatal AZT-containing cART in the mothers was 
associated with increased risk of clinically relevant anemia, cor-
roborating the previously described toxicity of AZT in the infant 
[14]. Surprisingly, no association between AZT-based neonatal 
PEP and clinically relevant anemia was found in our analysis, and 
the difference in RBC count at 1 and 24 months, although statis-
tically significant, was far from clinical relevance. We hypothesize 
that the small sample size and the short duration of neonatal PEP 
contributed to this lack of association.
The present study has several limitations. First, the relatively 
limited size of the study population influences the significance of 
statistical analysis, especially within subgroups. As an example, 
a possible influence of maternal cART regimens on lymphocyte 
subsets could not be completely ruled out, because even though 
no significant association with maternal cART was shown, the 
great diversity of cART regimes did not allow for deeper analysis. 
Second, this retrospective study relies only on the experience of a 
single center, and therefore the results may not be representative 
of the entire HEU population. Third, although cell counts and 
hemoglobin levels were compared with age-dependant normal 
ranges, a control group of HIV-unexposed infants is lacking. 
Nevertheless, because of the change of paradigm in the 2016 
Swiss recommendations for prevention of MTCT [4], this study 
was the first opportunity to analyze the impact of AZT-based 
neonatal PEP on lymphocyte subsets and hematological param-
eters in a well-defined cohort of HEU children.
CONCLUSIONS
Lymphocyte subsets in HEU infants receiving neonatal PEP did 
not differ from those of infants not receiving PEP but did show 
nonsignificant trends of lower adjusted means. Even though 
these observations are of questionable clinical significance, it 
remains unclear whether the effect of postnatal AZT exposure 
might have an impact on the overall health of HEU infants or 
might contribute to the previously observed higher incidence of 
infection in HEU infants within their first 2 years of life [5–7]. 
As other high-income countries may soon follow the Swiss ex-
ample and revisit their neonatal PEP recommendations, further 
studies to investigate the impact of postnatal AZT exposure in 
larger cohorts of HEU infants should be pursued.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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